Olema Pharmaceuticals
OLMA
128 hedge funds and large institutions have $626M invested in Olema Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 51 increasing their positions, 34 reducing their positions, and 26 closing their positions.
305% more call options, than puts
Call options by funds: $1.93M | Put options by funds: $477K
50% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 34
12% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 26
3.18% more ownership
Funds ownership: 100.34% → 103.52% (+3.2%)
2% more funds holding
Funds holding: 126 → 128 (+2)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
1% less capital invested
Capital invested by funds: $635M → $626M (-$8.72M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$34.8M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$8.64M |
| 3 |
BlackRock
New York
|
+$8.49M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$8.4M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$7.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$13.3M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$12.7M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$12.6M |
| 4 |
B
Braidwell
Stamford,
Connecticut
|
-$7.97M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$7.03M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
Comerica Bank
Dallas,
Texas
| – | -$4.01K | -354 | Closed |
|
152
US Bancorp
Minneapolis,
Minnesota
| – | -$1.78K | -157 | Closed |
|
|
AWM
153
Avior Wealth Management
Omaha,
Nebraska
| – | -$67 | -6 | Closed |
|
OLMA Hedge Fund Activity: Q2 2024 in Review
128 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Olema Pharmaceuticals (OLMA) for Q2 2024, worth a combined $626M — down 1.4% from $635M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new OLMA positions and 26 closed out — a net gain of 3 holders — while 51 added to existing stakes and 34 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $34.8M. The largest seller was State Street, cutting an estimated $13.3M.
- 128 institutional investors held Olema Pharmaceuticals (OLMA) as of Q2 2024, up from 126 in Q1 2024.
- Funds reported $626M of Olema Pharmaceuticals stock for Q2 2024, down 1.4% quarter-over-quarter.
- 29 funds opened new Olema Pharmaceuticals positions in Q2 2024 and 26 closed out, a net change of +3 holders.
- The largest Olema Pharmaceuticals buyer in Q2 2024 was Point72 Asset Management, an estimated $34.8M added.
- The largest Olema Pharmaceuticals seller in Q2 2024 was State Street, an estimated $13.3M sold.
Based on aggregated 13F filings for Q2 2024.